GAA
EDIT icon

Green Alpha Advisors’s Editas Medicine EDIT Stock Holding History

Green Alpha Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$506K Sell
156,046
-4,096
-3% -$12K 0.34% 68
2026
Q1 		$396K Sell
160,142
-978
-0.6% -$2.07K 0.39% 68
2025
Q4 		$330K Buy
161,120
+14,708
+10% +$42.5K 0.3% 86
2025
Q3 		$508K Sell
146,412
-24,370
-14% -$68K 0.49% 62
2025
Q2 		$376K Sell
170,782
-13,121
-7% -$21.5K 0.36% 77
2025
Q1 		$213K Buy
183,903
+72,275
+65% +$106K 0.23% 94
2024
Q4 		$142K Buy
111,628
+68,295
+158% +$174K 0.11% 137
2024
Q3 		$148K Buy
43,333
+13,066
+43% +$56.9K 0.12% 128
2024
Q2 		$141K Sell
30,267
-15,818
-34% -$89.2K 0.11% 125
2024
Q1 		$342K Buy
46,085
+163
+0.4% +$1.35K 0.25% 117
2023
Q4 		$465K Sell
45,922
-31,266
-41% -$274K 0.34% 110
2023
Q3 		$602K Buy
77,188
+15,343
+25% +$132K 0.46% 81
2023
Q2 		$509K Buy
61,845
+3,174
+5% +$27.7K 0.33% 106
2023
Q1 		$425K Sell
58,671
-984
-2% -$8.75K 0.3% 114
2022
Q4 		$529K Buy
59,655
+2,857
+5% +$31.4K 0.44% 92
2022
Q3 		$695K Sell
56,798
-283,146
-83% -$4.41M 0.59% 77
2022
Q2 		$4.02M Buy
339,944
+291,531
+602% +$3.91M 0.92% 34
2022
Q1 		$921K Buy
48,413
+12,199
+34% +$227K 0.62% 69
2021
Q4 		$961K Buy
36,214
+4,552
+14% +$157K 0.65% 77
2021
Q3 		$1.3M Buy
31,662
+737
+2% +$40.4K 0.9% 41
2021
Q2 		$1.75M Buy
30,925
+20,372
+193% +$752K 1.19% 21
2021
Q1 		$443K Buy
10,553
+4,517
+75% +$257K 0.44% 85
2020
Q4 		$423K Buy
+6,036
New +$248K 0.51% 73

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Green Alpha Advisors's EDIT Position: Q2 2026 in Review

Green Alpha Advisors reduced its Editas Medicine (EDIT) stake by 2.6% in Q2 2026, selling an estimated $12K and leaving 156,046 shares worth $506K. The position accounts for 0.34% of the portfolio, ranked #68.

Green Alpha Advisors first reported a position in EDIT in Q4 2020 and has held it in 23 quarters since. The position peaked at $4.02M in Q2 2022. 214 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Green Alpha Advisors held 156,046 shares of Editas Medicine worth $506K as of Q2 2026.
  • Green Alpha Advisors sold 4,096 Editas Medicine shares in Q2 2026, an estimated $12K.
  • Editas Medicine made up 0.34% of Green Alpha Advisors's portfolio in Q2 2026, its #68 holding.
  • Green Alpha Advisors first reported a position in Editas Medicine in Q4 2020 and has held it in 23 quarters since.
  • Green Alpha Advisors's Editas Medicine position peaked at $4.02M in Q2 2022.
  • 214 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Green Alpha Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.